Challenges and Opportunities of a Multi-Institutional Treatment Guideline for Wilms Tumor in Low-Middle-Income Countries-A Report from the Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA).
Patricia Valverde, Thelma Velasquez, Roberta Ortiz, Soad Linneth Fuentes-Alabi, Armando Peña, José Fernando Gonzalez, Tito Luis Gutierrez, Luis Enrique Melendez, Enrique Tome, Magda Arreola, Maria Grazia Valsecchi, Valeria Colombo, Sandra Luna-Fineman, Jessica Blanco-Lopez, Monika L Metzger, Filippo Spreafico
{"title":"Challenges and Opportunities of a Multi-Institutional Treatment Guideline for Wilms Tumor in Low-Middle-Income Countries-A Report from the Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA).","authors":"Patricia Valverde, Thelma Velasquez, Roberta Ortiz, Soad Linneth Fuentes-Alabi, Armando Peña, José Fernando Gonzalez, Tito Luis Gutierrez, Luis Enrique Melendez, Enrique Tome, Magda Arreola, Maria Grazia Valsecchi, Valeria Colombo, Sandra Luna-Fineman, Jessica Blanco-Lopez, Monika L Metzger, Filippo Spreafico","doi":"10.1002/pbc.31616","DOIUrl":null,"url":null,"abstract":"<p><p>Since 2000, centers across Central America have shared treatment guidelines for Wilms tumor, using histology (anaplasia present or absent) and tumor stage to stratify patients into low-, intermediate-, and high-risk groups. Weekly virtual tumor board meetings involving local and international experts were held to ensure consistent treatment assignments. We analyzed data from 367 children with unilateral tumors treated per these guidelines. Five-year abandonment-sensitive event-free and overall survival estimates were: low risk 82% ± 3.8% and 86% ± 3.6%, intermediate risk 50% ± 3.4% and 60% ± 3.4%, and high risk 36% ± 7.6% and 45% ± 7.9%. Survival outcomes were suboptimal, primarily due to advanced disease in fragile children at presentation and abandonment of treatment.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31616"},"PeriodicalIF":2.4000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pbc.31616","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Since 2000, centers across Central America have shared treatment guidelines for Wilms tumor, using histology (anaplasia present or absent) and tumor stage to stratify patients into low-, intermediate-, and high-risk groups. Weekly virtual tumor board meetings involving local and international experts were held to ensure consistent treatment assignments. We analyzed data from 367 children with unilateral tumors treated per these guidelines. Five-year abandonment-sensitive event-free and overall survival estimates were: low risk 82% ± 3.8% and 86% ± 3.6%, intermediate risk 50% ± 3.4% and 60% ± 3.4%, and high risk 36% ± 7.6% and 45% ± 7.9%. Survival outcomes were suboptimal, primarily due to advanced disease in fragile children at presentation and abandonment of treatment.
期刊介绍:
Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.